Cargando…
VEGF signalling enhances lesion burden in KRIT1 deficient mice
The exact molecular mechanisms underlying CCM pathogenesis remain a complicated and controversial topic. Our previous work illustrated an important VEGF signalling loop in KRIT1 depleted endothelial cells. As VEGF is a major mediator of many vascular pathologies, we asked whether the increased VEGF...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933401/ https://www.ncbi.nlm.nih.gov/pubmed/31746130 http://dx.doi.org/10.1111/jcmm.14773 |
_version_ | 1783483206356434944 |
---|---|
author | DiStefano, Peter V. Glading, Angela J. |
author_facet | DiStefano, Peter V. Glading, Angela J. |
author_sort | DiStefano, Peter V. |
collection | PubMed |
description | The exact molecular mechanisms underlying CCM pathogenesis remain a complicated and controversial topic. Our previous work illustrated an important VEGF signalling loop in KRIT1 depleted endothelial cells. As VEGF is a major mediator of many vascular pathologies, we asked whether the increased VEGF signalling downstream of KRIT1 depletion was involved in CCM formation. Using an inducible KRIT1 endothelial‐specific knockout mouse that models CCM, we show that VEGFR2 activation plays a role in CCM pathogenesis in mice. Inhibition of VEGFR2 using a specific inhibitor, SU5416, significantly decreased the number of lesions formed and slightly lowered the average lesion size. Notably, VEGFR2 inhibition also decreased the appearance of lesion haemorrhage as denoted by the presence of free iron in adjacent tissues. The presence of free iron correlated with increased microvessel permeability in both skeletal muscle and brain, which was completely reversed by SU5416 treatment. Finally, we show that VEGFR2 activation is a common downstream consequence of KRIT1, CCM2 and CCM3 loss of function, though the mechanism by which VEGFR2 activation occurs likely varies. Thus, our study clearly shows that VEGFR2 activation downstream of KRIT1 depletion enhances the severity of CCM formation in mice, and suggests that targeting VEGF signalling may be a potential future therapy for CCM. |
format | Online Article Text |
id | pubmed-6933401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69334012020-01-01 VEGF signalling enhances lesion burden in KRIT1 deficient mice DiStefano, Peter V. Glading, Angela J. J Cell Mol Med Original Articles The exact molecular mechanisms underlying CCM pathogenesis remain a complicated and controversial topic. Our previous work illustrated an important VEGF signalling loop in KRIT1 depleted endothelial cells. As VEGF is a major mediator of many vascular pathologies, we asked whether the increased VEGF signalling downstream of KRIT1 depletion was involved in CCM formation. Using an inducible KRIT1 endothelial‐specific knockout mouse that models CCM, we show that VEGFR2 activation plays a role in CCM pathogenesis in mice. Inhibition of VEGFR2 using a specific inhibitor, SU5416, significantly decreased the number of lesions formed and slightly lowered the average lesion size. Notably, VEGFR2 inhibition also decreased the appearance of lesion haemorrhage as denoted by the presence of free iron in adjacent tissues. The presence of free iron correlated with increased microvessel permeability in both skeletal muscle and brain, which was completely reversed by SU5416 treatment. Finally, we show that VEGFR2 activation is a common downstream consequence of KRIT1, CCM2 and CCM3 loss of function, though the mechanism by which VEGFR2 activation occurs likely varies. Thus, our study clearly shows that VEGFR2 activation downstream of KRIT1 depletion enhances the severity of CCM formation in mice, and suggests that targeting VEGF signalling may be a potential future therapy for CCM. John Wiley and Sons Inc. 2019-11-20 2020-01 /pmc/articles/PMC6933401/ /pubmed/31746130 http://dx.doi.org/10.1111/jcmm.14773 Text en © 2019 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for cellular and Molecular Medicine and John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles DiStefano, Peter V. Glading, Angela J. VEGF signalling enhances lesion burden in KRIT1 deficient mice |
title | VEGF signalling enhances lesion burden in KRIT1 deficient mice |
title_full | VEGF signalling enhances lesion burden in KRIT1 deficient mice |
title_fullStr | VEGF signalling enhances lesion burden in KRIT1 deficient mice |
title_full_unstemmed | VEGF signalling enhances lesion burden in KRIT1 deficient mice |
title_short | VEGF signalling enhances lesion burden in KRIT1 deficient mice |
title_sort | vegf signalling enhances lesion burden in krit1 deficient mice |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933401/ https://www.ncbi.nlm.nih.gov/pubmed/31746130 http://dx.doi.org/10.1111/jcmm.14773 |
work_keys_str_mv | AT distefanopeterv vegfsignallingenhanceslesionburdeninkrit1deficientmice AT gladingangelaj vegfsignallingenhanceslesionburdeninkrit1deficientmice |